申请人:HOFFMANN LA ROCHE
公开号:WO2011161006A1
公开(公告)日:2011-12-29
The present invention relates to a compound of general formula (I) wherein R1, R2 and R3 are independently from each other hydrogen, lower alkyl, lower alkoxy, cycloalkyl, lower alkyl substituted by halogen or S-lower alkyl; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer thereof. It has been found that the compounds of general formula (I) are good inhibitors of the glycine transporter 1 (GlyT-1), and that they have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors. The compounds may be used in the treatment of neurological and neuropsychiatric disorders.
本发明涉及一种通式(I)的化合物,其中R1、R2和R3彼此独立地为氢、较低烷基、较低烷氧基、环烷基、通过卤素或S-较低烷基取代的较低烷基;或者为药学上可接受的酸盐,或者为消旋混合物,或者为其相应的对映体和/或光学异构体。已发现通式(I)的化合物是甘氨酸转运蛋白1(GlyT-1)的良好抑制剂,并且它们对甘氨酸转运蛋白2(GlyT-2)抑制剂具有良好的选择性。这些化合物可用于治疗神经系统和神经精神障碍。